Cancer testing

Molecular testing has become useful in clinical practice to detect actionable genomic alterations for both diagnostic and therapeutic purposes. The use of molecular testing and biomarker-driven therapy has undergone marked growth and development for the management of cancer in recent years. Precision Oncology is the form of medicine which uses cancer treatments that are targeted to individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given cancer patient from other patients with similar clinical presentations. 

Methods that we use and develop encompass: PCR, reverse transcription PCR, real time PCR, methylation specific PCR followed by sequencing, DNA microarray and bisulfite genomic sequencing, “SNAPSHOT” assay, ELISA/LFA immunoassay and proteomic assay. We have analyzed genetic, epigenetic, genomic and proteomic characteristics (we call this “multiplex molecular analysis”) in a procedure called “cansolution”

This is an example of our cancer chip. Goodgene has developed a multiplex PCR based DNA microarray (DNA chip) technology, by which it is possible to analyze , expression and methylation of more than hundreds of cancer-related key genes.

NOT AUTHORIZED OR CLEARED FOR CLINICAL USE IN THE USA, RESEARCH USE ONLY

Example of amplification plot used in one of our PCR test for cancer study

Cocco, E., Scaltriti, M. & Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15, 731–747 (2018).